Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 6,949,532

« Back to Dashboard
Patent 6,949,532 protects ASMANEX TWISTHALER and is included in one NDA.

Protection for ASMANEX TWISTHALER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty patent family members in twenty-six countries.

Summary for Patent: 6,949,532

Title: Use of mometasone furoate for treating airway passage and lung diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/763,295
Patent Claim Types:
see list of patent claims
Use;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-002Feb 1, 2008RXNo6,949,532*PED<disabled>
Merck Sharp Dohme
ASMANEX TWISTHALER
mometasone furoate
POWDER;INHALATION021067-001Mar 30, 2005RXYes6,949,532*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,949,532

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications. They represent opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,889,015 Use of mometasone furoate for treating lower airway passage and lung diseases<disabled in preview>
6,677,323 Use of mometasone furoate for treating airway passage and lung diseases<disabled in preview>
6,677,322 Use of mometasone furoate for treating airway passage and lung diseases<disabled in preview>
6,956,030 Use of mometasone furoate for treating upper airway diseases<disabled in preview>
5,837,699 Use of mometasone furoate for treating upper airway passage diseases<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,949,532

Country Document Number Publication Date
Hungary9602043Sep 30, 1996
Spain2368827Nov 22, 2011
Australia691880May 28, 1998
Spain2173947Nov 01, 2002
Hungary227837May 02, 2012
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc